{"id":34,"date":"2020-09-23T23:41:25","date_gmt":"2020-09-23T22:41:25","guid":{"rendered":"http:\/?page_id=34"},"modified":"2024-06-27T08:25:26","modified_gmt":"2024-06-27T07:25:26","slug":"publications","status":"publish","type":"page","link":"http:\/\/www.neuropharmacologie.universite-paris-saclay.fr\/?page_id=34","title":{"rendered":"Publications"},"content":{"rendered":"\n

2024<\/h2>\n\n\n\n

Nguyen, T. M. L., F. Jollant, L. Tritschler, R. Colle, E. Corruble and A. M. Gardier (2024). \u00ab\u00a0[Ketamine and suicidal behavior: Contribution of animal models of aggression-impulsivity to understanding its mechanism of action].\u00a0\u00bb Ann Pharm Fr 82(1): 3-14.<\/a><\/p>\n\n\n\n

<\/p>\n\n\n\n

Nguyen, T. M. L., J.-P. Guilloux, C. Defaix, I. Mendez-David, I. Etting, J.-C. Alvarez, J. C. McGowan, J. N. Highland, P. Zanos, J. Lovett, R. Moaddel, E. Corruble, D. J. David, T. D. Gould, C. A. Denny and A. M. Gardier (2024).\u00a0\u00bbKetamine metabolism via hepatic CYP450 isoforms contributes to its sustained antidepressant actions.\u00a0\u00bb bioRxiv<\/a><\/p>\n\n\n\n

<\/p>\n\n\n\n

Mahfoudhi, S., C. Mory, J. Le Ven, F. Coudore, N. El Helali, F. Safta and A. Le Monnier (2024). \u00ab\u00a0Simultaneous determination of oxacillin and cloxacillin in plasma and CSF using turbulent flow liquid chromatography coupled to high-resolution mass spectrometry: Application in therapeutic drug monitoring.\u00a0\u00bb J Chromatogr B Analyt Technol Biomed Life Sci 1233: 123979.<\/a><\/p>\n\n\n\n

<\/p>\n\n\n\n

Golbaghi, N., S. Naeimi, A. Darvishi, N. Najari and S. Cussotto (2024). \u00ab\u00a0Probiotics in autism spectrum disorder: Recent insights from animal models.\u00a0\u00bb Autism: 13623613241246911.<\/a><\/p>\n\n\n\n

<\/p>\n\n\n\n

Etienne, J., A. Boutigny, D. J. David, E. Deflesselle, F. Gressier, L. Becquemont, E. Corruble and R. Colle (2024). \u00ab\u00a0Habenular volume changes after venlafaxine treatment in patients with major depression.\u00a0\u00bb Psychiatry Clin Neurosci.<\/a><\/p>\n\n\n\n

<\/p>\n\n\n\n

Chang, W. L., K. Tegang, B. A. Samuels, M. Saxe, J. Wichmann, D. J. David, I. M. David, A. Augustin, H. Fischer, S. Golling, J. Lamerz, D. Roth, M. Graf, S. Zoffmann, L. Santarelli, R. Jagasia and R. Hen (2024). \u00ab\u00a0Pharmacological Enhancement of Adult Hippocampal Neurogenesis Improves Behavioral Pattern Separation in Young and Aged Mice.\u00a0\u00bb bioRxiv<\/a>.<\/p>\n\n\n\n

<\/p>\n\n\n\n

2023<\/h2>\n\n\n\n

Nguyen, T. M. L., F. Jollant, L. Tritschler, R. Colle, E. Corruble and A. M. Gardier (2023). \u00ab\u00a0Pharmacological Mechanism of Ketamine in Suicidal Behavior Based on Animal Models of Aggressiveness and Impulsivity: A Narrative Review.\u00a0\u00bb Pharmaceuticals (Basel) 16(4).<\/a><\/p>\n\n\n\n

<\/p>\n\n\n\n

Nguyen, T. M. L., C. Defaix, I. Mendez-David, L. Tritschler, I. Etting, J. C. Alvarez, W. Choucha, R. Colle, E. Corruble, D. J. David and A. M. Gardier (2023). \u00ab\u00a0Intranasal (R, S)-ketamine delivery induces sustained antidepressant effects associated with changes in cortical balance of excitatory\/inhibitory synaptic activity.\u00a0\u00bb Neuropharmacology 225: 109357.<\/a><\/p>\n\n\n\n

<\/p>\n\n\n\n

Mendez-David, I., D. J. David, C. Delomenie, L. Tritchler, J. M. Beaulieu, R. Colle, E. Corruble, A. M. Gardier and R. Hen (2023). \u00ab\u00a0A complex relation between levels of adult hippocampal neurogenesis and expression of the immature neuron marker doublecortin.\u00a0\u00bb Hippocampus.<\/a><\/p>\n\n\n\n

<\/p>\n\n\n\n

Jollant, F., R. Colle, T. M. L. Nguyen, E. Corruble, A. M. Gardier, M. Walter, M. Abbar and G. Wagner (2023). \u00ab\u00a0Ketamine and esketamine in suicidal thoughts and behaviors: a systematic review.\u00a0\u00bb Ther Adv Psychopharmacol 13: 20451253231151327.<\/a><\/p>\n\n\n\n

<\/p>\n\n\n\n

Doan, J., C. Defaix, I. Mendez-David, A. M. Gardier, R. Colle, E. Corruble, J. C. McGowan, D. J. David, J. P. Guilloux and L. Tritschler (2023). \u00ab\u00a0Intrahippocampal injection of a selective blocker of NMDA receptors containing the GluN2B subunit, Ro25-6981, increases glutamate neurotransmission and induces antidepressant-like effects.\u00a0\u00bb Fundam Clin Pharmacol.<\/a><\/p>\n\n\n\n

<\/p>\n\n\n\n

2022<\/h2>\n\n\n\n

<\/p>\n\n\n\n

<\/p>\n\n\n\n

Ait Tayeb, A. E. K., R. Colle, K. Chappell, K. El-Asmar, C. Acquaviva-Bourdain, D. J. David, S. Trabado, P. Chanson, B. Feve, L. Becquemont, C. Verstuyft and E. Corruble (2023). \u00ab\u00a0Metabolomic profiles of 38 acylcarnitines in major depressive episodes before and after treatment.\u00a0\u00bb Psychol Med: 1-10.<\/a><\/p>\n\n\n\n

<\/p>\n\n\n\n

Mesdom, P., R. Colle, L. Becquemont, K. Chappell, D. J. David, I. Mendez-David, E. Corruble and C. Verstuyft (2022). \u00ab\u00a0Tobacco use is associated with low peripheral beta-arrestin 1 levels in major depression: A preliminary report.\u00a0\u00bb Drug Alcohol Depend 240: 109653.<\/a><\/p>\n\n\n\n

<\/p>\n\n\n\n

Lebeau, R. H., I. Mendez-David, L. Kucynski-Noyau, C. Henry, D. Attali, M. Plaze, R. Colle, E. Corruble, A. M. Gardier, R. Gaillard, J. P. Guilloux and D. J. David (2022). \u00ab\u00a0Peripheral proteomic changes after electroconvulsive seizures in a rodent model of non-response to chronic fluoxetine.\u00a0\u00bb Front Pharmacol 13: 993449.<\/a><\/p>\n\n\n\n

<\/p>\n\n\n\n

Poinsignon, V., R. Colle, K. E. Asmar, I. Mendez-David, D. J. David, A. E. K. Ait Tayeb, K. Chappell, F. Gressier, H. Herrero, B. Feve, L. Becquemont, E. Corruble and C. Verstuyft (2022). \u00ab\u00a0The GG genotype of the serotonin 4 receptor genetic polymorphism, rs1345697, is associated with lower remission rates after antidepressant treatment: Findings from the METADAP cohort.\u00a0\u00bb J Affect Disord 299: 335-343.<\/a><\/p>\n\n\n\n

<\/p>\n\n\n\n

Nguyen, T. M. L., J. C. McGowan and A. M. Gardier (2022). \u00ab\u00a0CYP 450 enzymes influence (R,S)-ketamine brain delivery and its antidepressant activity.\u00a0\u00bb Neuropharmacology 206: 108936.<\/a><\/p>\n\n\n\n

<\/p>\n\n\n\n

Mendez-David, I., R. Schofield, L. Tritschler, R. Colle, J. P. Guilloux, A. M. Gardier, E. Corruble, R. Hen and D. J. David (2022). \u00ab\u00a0Reviving through human hippocampal newborn neurons.\u00a0\u00bb Encephale 48(2): 179-187.<\/a><\/p>\n\n\n\n

2021<\/h2>\n\n\n\n

Reach, P., I. Lazareth, F. Coudore, A. Stansal, R. Attal, U. Michon-Pasturel, P. Ghaffari, A. Yannoutsos, H. Beaussier, E. Sacco, M. Wang, P. Priollet, J. P. Lefaucheur and M. Zuber (2021). \u00ab\u00a0A reappraisal of the presence of small or large fiber neuropathy in patients with erythromelalgia.\u00a0\u00bb Neurophysiol Clin 51(4): 349-355.<\/a><\/p>\n\n\n\n

<\/p>\n\n\n\n

Mongongu, C., F. Coudore, V. Domergue, M. Ericsson, C. Buisson and A. Marchand (2021). \u00ab\u00a0Detection of LongR(3) -IGF-I, Des(1-3)-IGF-I, and R(3) -IGF-I using immunopurification and high resolution mass spectrometry for antidoping purposes.\u00a0\u00bb Drug Test Anal 13(7): 1256-1269.<\/a><\/p>\n\n\n\n

<\/p>\n\n\n\n

Dallerac, G., X. Li, P. Lecouflet, N. Morisot, S. Sacchi, R. Asselot, T. H. Pham, B. Potier, D. J. G. Watson, S. Schmidt, G. Levasseur, P. Fossat, A. Besedin, J. M. Rivet, J. T. Coyle, G. Collo, L. Pollegioni, J. Kehr, M. Galante, K. C. Fone, A. M. Gardier, T. Freret, A. Contarino, M. J. Millan and J. P. Mothet (2021). \u00ab\u00a0Dopaminergic neuromodulation of prefrontal cortex activity requires the NMDA receptor coagonist d-serine.\u00a0\u00bb Proc Natl Acad Sci U S A 118(23).<\/a><\/p>\n\n\n\n

<\/p>\n\n\n\n

Balayssac, D., B. Pereira, P. Cuq, J. Douris, L. Ferrari, E. Boutet-Robinet, M. Lechevrel, C. Demeilliers, P. Rat, F. Coudore, E. Verron, B. Lacarelle, J. Guitton, A. Courtois, D. Allorge, S. Pain, M. Guerbet, A. Collin, B. Vennat, G. Brousse, N. Authier and C. Laporte (2021). \u00ab\u00a0Perception of pharmacy students toward opioid-related disorders and roles of community pharmacists: A French nationwide cross-sectional study.\u00a0\u00bb Subst Abus 42(4): 706-715.<\/a><\/p>\n\n\n\n

<\/p>\n\n\n\n

Ait Tayeb, A. E. K., R. Colle, K. El-Asmar, K. Chappell, C. Acquaviva-Bourdain, D. J. David, S. Trabado, P. Chanson, B. Feve, L. Becquemont, C. Verstuyft and E. Corruble (2021). \u00ab\u00a0Plasma acetyl-l-carnitine and l-carnitine in major depressive episodes: a case-control study before and after treatment.\u00a0\u00bb Psychol Med: 1-10.<\/a><\/p>\n\n\n\n

2020<\/strong><\/h2>\n\n\n\n

Petitjean, G., F. Aman-Pommier, F. Coudore, N. El Helali and A. Le Monnier (2020). \u00ab\u00a0A rapid, automatic and accurate assay for quantifying temocillin in human serum and CSF using turbulent flow liquid chromatography coupled to high-resolution mass spectrometry. Clinical application.\u00a0\u00bb Biomed Chromatogr 34(2): e4759.<\/a><\/p>\n\n\n\n

<\/p>\n\n\n\n

Mongongu, C., E. M. Moussa, F. Semence, I. Roulland, M. Ericsson, F. Coudore, A. Marchand and C. Buisson (2020). \u00ab\u00a0Use of capillary dried blood for quantification of intact IGF-I by LC-HRMS for antidoping analysis.\u00a0\u00bb Bioanalysis 12(11): 737-752.<\/a><\/p>\n\n\n\n

<\/p>\n\n\n\n

Colle, R., K. El Asmar, C. Verstuyft, P. M. Lledo, F. Lazarini, K. Chappell, E. Deflesselle, A. E. K. Ait Tayeb, B. Falissard, E. Duron, S. Rotenberg, J. F. Costemale-Lacoste, D. J. David, F. Gressier, A. M. Gardier, T. Hummel, L. Becquemont and E. Corruble (2020). \u00ab\u00a0The olfactory deficits of depressed patients are restored after remission with venlafaxine treatment.\u00a0\u00bb Psychol Med: 1-9.<\/a><\/p>\n\n\n\n

<\/p>\n\n\n\n

Pham, T. H., C. Defaix, T. M. L. Nguyen, I. Mendez-David, L. Tritschler, D. J. David and A. M. Gardier (2020). \u00ab\u00a0Cortical and raphe GABAA, AMPA receptors and glial GLT-1 glutamate transporter contribute to the sustained antidepressant activity of ketamine.\u00a0\u00bb Pharmacol Biochem Behav 192<\/strong>: 172913.<\/a><\/p>\n\n\n\n

<\/p>\n\n\n\n

Petitjean, G., F. Aman-Pommier, F. Coudore, N. El Helali and A. Le Monnier (2020). \u00ab\u00a0A rapid, automatic and accurate assay for quantifying temocillin in human serum and CSF using turbulent flow liquid chromatography coupled to high-resolution mass spectrometry. Clinical application.\u00a0\u00bb Biomed Chromatogr 34<\/strong>(2): e4759.<\/a><\/p>\n\n\n\n

<\/p>\n\n\n\n

Mongongu, C., E. M. Moussa, F. Semence, I. Roulland, M. Ericsson, F. Coudore, A. Marchand and C. Buisson (2020). \u00ab\u00a0Use of capillary dried blood for quantification of intact IGF-I by LC-HRMS for antidoping analysis.\u00a0\u00bb Bioanalysis 12<\/strong>(11): 737-752.<\/a><\/p>\n\n\n\n

<\/p>\n\n\n\n

Faye, C., R. Hen, B. P. Guiard, C. A. Denny, A. M. Gardier, I. Mendez-David and D. J. David (2020). \u00ab\u00a0Rapid Anxiolytic Effects of RS67333, a Serotonin Type 4 Receptor Agonist, and Diazepam, a Benzodiazepine, Are Mediated by Projections From the Prefrontal Cortex to the Dorsal Raphe Nucleus.\u00a0\u00bb Biol Psychiatry 87<\/strong>(6): 514-525.<\/a><\/p>\n\n\n\n

<\/p>\n\n\n\n

Colle, R., P. Masson, C. Verstuyft, B. Feve, E. Werner, C. Boursier-Neyret, B. Walther, D. J. David, B. Boniface, B. Falissard, P. Chanson,<\/a>E. Corruble and L. Becquemont (2020). \u00ab\u00a0Peripheral tryptophan, serotonin, kynurenine, <\/a>and<\/a> their metabolites in major depression: A case-control study.\u00a0\u00bb Psychiatry Clin Neurosci 74<\/strong>(2): 112-117.<\/a><\/p>\n\n\n\n

<\/p>\n\n\n\n

Chen<\/a>, B. K., I. Mendez-David, V. M. Luna, C. Faye, A. M. Gardier, D. J. David and C. A. Denny (2020). \u00ab\u00a0Prophylactic efficacy of 5-HT4R agonists against stress.\u00a0\u00bb Neuropsychopharmacology 45<\/strong>(3): 542-552.<\/a><\/p>\n\n\n\n

<\/p>\n\n\n\n

Chen, B. K., V. M. Luna, C. T. LaGamma, X. Xu, S. X. Deng, R. F. Suckow, T. B. Cooper, A. Shah, R. A. Brachman, I. Mendez-David, D. J. David, A. M. Gardier, D. W. Landry and C. A. Denny (2020). \u00ab\u00a0Sex-specific neurobiological actions of prophylactic (R,S)-ketamine, (2R,6R)-hydroxynorketamine, and (2S,6S)-hydroxynorketamine.\u00a0\u00bb <\/a>Neuropsychopharmacology<\/a> 45<\/strong>(9): 1545-1556.<\/a><\/p>\n\n\n\n

<\/p>\n\n\n\n

Agasse, F., I. Mendez-David, W. Christaller, R. Carpentier, B. Y. Braz, D. J. David, F. Saudou and S. Humbert (2020). \u00ab\u00a0Chronic Corticosterone Elevation Suppresses Adult Hippocampal Neurogenesis by Hyperphosphorylating Huntingtin.\u00a0\u00bb Cell Rep 32<\/strong>(1): 107865.<\/a><\/p>\n\n\n\n

<\/p>\n\n\n\n

2019<\/strong><\/h2>\n\n\n\n

Tutakhail, A., Q. A. Nazari, S. Khabil, A. Gardier and F. Coudore (2019). \u00ab\u00a0Muscular and mitocho<\/a>ndrial effects of long-term fluoxetine treatment in mice, combined with physical endurance exercise on treadmill.\u00a0\u00bb Life Sci 232<\/strong>: 116508.<\/a><\/p>\n\n\n\n

<\/p>\n\n\n\n

Pham, T. H. and A. M. Gardier (2019). \u00ab\u00a0Fast-acting antidepressant activity of ketamine: highlights on brain serotonin, glutamate, and GABA neurotransmission in preclinical studies.\u00a0\u00bb Pharmacol Ther 199<\/strong>: 58-90.<\/a><\/p>\n\n\n\n

<\/p>\n\n\n\n

Feng, J., S. Lepetre-Mouelhi, A. Gautier, S. Mura, C. Cailleau, F. Coudore, M. Hamon and P. Couvreur (2019). \u00ab\u00a0A new painkiller nanomedicine to bypass the blood-brain barrier and the use of morphine.\u00a0\u00bb Sci Adv 5<\/strong>(2): eaau5148.<\/a><\/p>\n\n\n\n

<\/p>\n\n\n\n

Doan, J., A. M. Gardier and L. Tritschler (2019). \u00ab\u00a0Role of adult-born granule cells in the hippocampal functions: Focus on the GluN2B-containing NMDA receptors.\u00a0\u00bb Eur Neuropsychopharmacol 29<\/strong>(10): 1065-1082.<\/a><\/p>\n\n\n\n

<\/p>\n\n\n\n

Colle, R., A. E. K. Ait Tayeb, P. Mesdom, M. de Menthon, L. Becquemont, C. Verstuyft, D. J. David, O. Lambotte and E. Corruble (2019). \u00ab\u00a0Methemoglobinemia as a biomarker of dapsone-induced mania severity.\u00a0\u00bb J Affect Disord 254<\/strong>: 122-123.<\/a><\/p>\n\n\n\n

<\/p>\n\n\n\n

Zhang, H., C. Zhang, J. Vincent, D. Zala, C. Benstaali, M. Sainlos, D. Grillo-Bosch, S. Daburon, F. Coussen, Y. Cho, D. J. David, F. Saudou, Y. Humeau and D. Choquet (2018). \u00ab\u00a0Modulation of AMPA receptor surface diffusion restores hippocampal plasticity and memory in Huntington’s disease models.\u00a0\u00bb Nat Commun 9<\/strong>(1): 4272.<\/a><\/p>\n\n\n\n

<\/p>\n\n\n\n

201<\/strong>8<\/h2>\n\n\n\n

Tutakhail, A., Q. A. Nazary, D. Lebsir, S. Kerdine-Romer and F. Coudore (2018). \u00ab\u00a0Induction of brain Nrf2-HO-1 pathway and antinociception after different physical training paradigms in mice.\u00a0\u00bb Life Sci209<\/strong>: 149-156.<\/a><\/p>\n\n\n\n

<\/p>\n\n\n\n

Tritschler, L., M. A. Kheirbek, Y. L. Dantec, I. Mendez-David, J. P. Guilloux, C. Faye, J. Doan, T. H. Pham, R. Hen, D. J. David and A. M. Gardier (2018). \u00ab\u00a0Optogenetic activation of granule cells in the dorsal dentate gyrus enhances dopaminergic neurotransmission in the Nucleus Accumbens.\u00a0\u00bb Neurosci Res 134<\/strong>: 56-60.<\/a><\/p>\n\n\n\n

<\/p>\n\n\n\n

Tritschler, L., R. Gaillard, A. M. Gardier, D. J. David and J. P. Guilloux (2018). \u00ab\u00a0[Consequences of the monoaminergic systems cross-talk in the antidepressant activity].\u00a0\u00bb Encephale 44<\/strong>(3): 264-273.<\/a><\/p>\n\n\n\n

<\/p>\n\n\n\n

Pham, T. H., C. Defaix, X. Xu, S. X. Deng, N. Fabresse, J. C. Alvarez, D. W. Landry, R. A. Brachman, C. A. Denny and A. M. Gardier (2018). \u00ab\u00a0Common Neurotransmission Recruited in (R,S)-Ketamine and (2R,6R)-Hydroxynorketamine-Induced Sustained Antidepressant-like Effects.\u00a0\u00bb Biol Psychiatry 84<\/strong>(1): e3-e6.<\/a><\/p>\n\n\n\n

<\/p>\n\n\n\n

Petit, A. C., K. El Asmar, D. J. David, A. M. Gardier, L. Becquemont, B. Feve, C. Verstuyft and E. Corruble (2018). \u00ab\u00a0The association of beta-arrestin2 polymorphisms with response to antidepressant treatment in depressed patients.\u00a0\u00bb Prog Neuropsychopharmacol Biol Psychiatry 81<\/strong>: 74-79.<\/a><\/p>\n\n\n\n

<\/p>\n\n\n\n

Felice, D., J. P. Guilloux, A. Pehrson, Y. Li, I. Mendez-David, A. M. Gardier, C. Sanchez and D. J. David (2018). \u00ab\u00a0Vortioxetine Improves Context Discrimination in Mice Through a Neurogenesis Independent Mechanism.\u00a0\u00bb Front Pharmacol 9<\/strong>: 204.<\/a><\/p>\n\n\n\n

<\/p>\n\n\n\n

Delmotte, J. B., A. Tutakhail, K. Abdallah, P. Reach, M. D’Ussel, G. Deplanque, H. Beaussier and F. Coudore (2018). \u00ab\u00a0Electrochemical Skin Conductance as a Marker of Painful Oxaliplatin-Induced Peripheral Neuropathy.\u00a0\u00bb Neurol Res Int 2018<\/strong>: 1254602.<\/a><\/p>\n\n\n\n

<\/p>\n\n\n\n

Delmotte, J. B., H. Beaussier, N. Auzeil, F. Massicot, O. Laprevote, E. Raymond and F. Coudore (2018). \u00ab\u00a0Is quantitative sensory testing helpful in the management of oxaliplatin neuropathy? a two-year clinical study.\u00a0\u00bb Cancer Treat Res Commun 17<\/strong>: 31-36.<\/a><\/p>\n\n\n\n

<\/p>\n\n\n\n

Deflesselle, E., R. Colle, L. Rigal, D. J. David, A. Vievard, S. Martin, L. Becquemont, C. Verstuyft and E. Corruble (2018). \u00ab\u00a0The TRKB rs2289656 genetic polymorphism is associated with acute suicide attempts in depressed patients: A transversal case control study.\u00a0\u00bb PLoS One 13<\/strong>(10): e0205648.<\/a><\/p>\n\n\n\n

<\/p>\n\n\n\n

Defaix, C., A. Solgadi, T. H. Pham, A. M. Gardier, P. Chaminade and L. Tritschler (2018). \u00ab\u00a0Rapid analysis of glutamate, glutamine and GABA in mice frontal cortex microdialysis samples using HPLC coupled to electrospray tandem mass spectrometry.\u00a0\u00bb J Pharm Biomed Anal 152<\/strong>: 31-38.<\/a><\/p>\n\n\n\n

<\/p>\n\n\n\n

Colle, R., F. Boichot, E. Bouteiller, C. Elie-Lefebvre, P. Hardy, D. J. David, C. Verstuyft and E. Corruble (2018). \u00ab\u00a0Restless Legs Syndrome and Schizophrenia: A Case Report.\u00a0\u00bb J Clin Psychopharmacol 38<\/strong>(1): 91-92.<\/a><\/p>\n\n\n\n

<\/p>\n\n\n\n

Colle, R., A. E. K. Ait Tayeb, P. Mesdom, M. de Menthon, L. Becquemont, C. Verstuyft, D. J. David, O. Lambotte and E. Corruble (2018). \u00ab\u00a0Methemoglobinemia as a biomarker of dapsone-induced mania severity.\u00a0\u00bb J Affect Disord.<\/a><\/p>\n\n\n\n

2017<\/strong><\/h2>\n\n\n\n

Pham, T. H., I. Mendez-David, C. Defaix, B. P. Guiard, L. Tritschler, D. J. David and A. M. Gardier (2017). \u00ab\u00a0Ketamine treatment involves medial prefrontal cortex serotonin to induce a rapid antidepressant-like activity in BALB\/cJ mice.\u00a0\u00bb Neuropharmacology 112<\/strong>(Pt A): 198-209.<\/a><\/p>\n\n\n\n

<\/p>\n\n\n\n

Mendez-David, I., J. P. Guilloux, M. Papp, L. Tritschler, E. Mocaer, A. M. Gardier, S. Bretin and D. J. David (2017). \u00ab\u00a0S 47445 Produces Antidepressant- and Anxiolytic-Like Effects through Neurogenesis Dependent and Independent Mechanisms.\u00a0\u00bb Front Pharmacol 8<\/strong>: 462.<\/a><\/p>\n\n\n\n

<\/p>\n\n\n\n

Mendez-David, I., C. Boursier, V. Domergue, R. Colle, B. Falissard, E. Corruble, A. M. Gardier, J. P. Guilloux and D. J. David (2017). \u00ab\u00a0Differential Peripheral Proteomic Biosignature of Fluoxetine Response in a Mouse Model of Anxiety\/Depression.\u00a0\u00bb Front Cell Neurosci 11<\/strong>: 237.<\/a><\/p>\n\n\n\n

<\/p>\n\n\n\n

Mekiri, M., A. M. Gardier, D. J. David and J. P. Guilloux (2017). \u00ab\u00a0Chronic corticosterone administration effects on behavioral emotionality in female c57bl6 mice.\u00a0\u00bb Exp Clin Psychopharmacol 25<\/strong>(2): 94-104.<\/a><\/p>\n\n\n\n

<\/p>\n\n\n\n

Lugert, S., T. Kremer, R. Jagasia, A. Herrmann, S. Aigner, C. Giachino, I. Mendez-David, A. M. Gardier, J. P. Carralot, H. Meistermann, A. Augustin, M. D. Saxe, J. Lamerz, G. Duran-Pacheco, A. Ducret, V. Taylor, D. J. David and C. Czech (2017). \u00ab\u00a0Glypican-2 levels in cerebrospinal fluid predict the status of adult hippocampal neurogenesis.\u00a0\u00bb Sci Rep 7<\/strong>: 46543.<\/a><\/p>\n\n\n\n

<\/p>\n\n\n\n

Guilloux, J. P., B. A. Samuels, I. Mendez-David, A. Hu, M. Levinstein, C. Faye, M. Mekiri, E. Mocaer, A. M. Gardier, R. Hen, A. Sors and D. J. David (2017). \u00ab\u00a0S 38093, a histamine H3 antagonist\/inverse agonist, promotes hippocampal neurogenesis and improves context discrimination task in aged mice.\u00a0\u00bb Sci Rep 7<\/strong>: 42946.<\/a><\/p>\n\n\n\n

<\/p>\n\n\n\n

Guilloux, J. P., A. M. Gardier and D. J. David (2017). \u00ab\u00a0New targets and modalities of antidepressant drugs development.\u00a0\u00bb La lettre du Pharmacologue 31<\/strong>(1): 12-18.<\/p>\n\n\n\n

<\/p>\n\n\n\n

Garcia-Garcia, A. L., Q. Meng, S. Canetta, A. M. Gardier, B. P. Guiard, C. Kellendonk, A. Dranovsky and E. D. Leonardo (2017). \u00ab\u00a0Serotonin Signaling through Prefrontal Cortex 5-HT1A Receptors during Adolescence Can Determine Baseline Mood-Related Behaviors.\u00a0\u00bb Cell Rep 18<\/strong>(5): 1144-1156.<\/a><\/p>\n\n\n\n

<\/p>\n\n\n\n

Felice, D., A. M. Gardier, C. S. Sanchez and D. J. David (2017). Innovative Solutions to the Development of Novel Antidepressants. Frontiers in Drug Discovery, Bentham Science Publishers. 2: <\/strong>3-43.<\/a><\/p>\n\n\n\n

<\/p>\n\n\n\n

Faye, C., J. C. McGowan, C. A. Denny and D. J. David (2017). \u00ab\u00a0Neurobiological mechanisms of stress resilience and implications for the aged population.\u00a0\u00bb Curr Neuropharmacol.<\/a><\/p>\n\n\n\n

<\/p>\n\n\n\n

Deflesselle, E., C. Verstuyft, A. C. Petit, P. Hardy, D. J. David, B. Falissard, B. Feve, L. Rigal, L. Becquemont, E. Corruble and R. Colle (2017). \u00ab\u00a0No impact of eight NTRK2 genetic polymorphisms on 6-month antidepressant efficacy in depressed patients.\u00a0\u00bb Pharmacogenomics 18<\/strong>(4): 349-357.<\/a><\/p>\n\n\n\n

<\/p>\n\n\n\n

Colle, R., S. Trabado, D. J. David, S. Brailly-Tabard, P. Hardy, B. Falissard, B. Feve, L. Becquemont, C. Verstuyft and E. Corruble (2017). \u00ab\u00a0Plasma BDNF Level in Major Depression: Biomarker of the Val66Met BDNF Polymorphism and of the Clinical Course in Met Carrier Patients.\u00a0\u00bb Neuropsychobiology 75<\/strong>(1): 39-45.<\/a><\/p>\n\n\n\n

<\/p>\n\n\n\n

Andriamamonjy, M., J. B. Delmotte, F. Savinelli, H. Beaussier and F. Coudore (2017). \u00ab\u00a0Quantification of Chronic Oxaliplatin-Induced Hypesthesia in Two Areas of the Hand.\u00a0\u00bb J Clin Neurophysiol 34<\/strong>(2): 126-131.<\/a><\/p>\n\n\n\n

<\/p>\n\n\n\n

2016<\/h2>\n\n\n\n

<\/p>\n\n\n\n

Siopi, E., M. Denizet, M. M. Gabellec, F. de Chaumont, J. C. Olivo-Marin, J. P. Guilloux, P. M. Lledo and F. Lazarini (2016). \u00ab\u00a0Anxiety- and Depression-Like States Lead to Pronounced Olfactory Deficits and Impaired Adult Neurogenesis in Mice.\u00a0\u00bb J Neurosci 36<\/strong>(2): 518-531.<\/a><\/p>\n\n\n\n

<\/p>\n\n\n\n

Samuels, B. A., I. Mendez-David, C. Faye, S. A. David, K. A. Pierz, A. M. Gardier, R. Hen and D. J. David (2016). \u00ab\u00a0Serotonin 1A and Serotonin 4 Receptors: Essential Mediators of the Neurogenic and Behavioral Actions of Antidepressants.\u00a0\u00bb Neuroscientist 22<\/strong>(1): 26-45.<\/a><\/p>\n\n\n\n

<\/p>\n\n\n\n

Qesseveur, G., A. C. Petit, H. T. Nguyen, L. Dahan, R. Colle, S. Rotenberg, I. Seif, P. Robert, D. David, J. P. Guilloux, A. M. Gardier, C. Verstuyft, L. Becquemont, E. Corruble and B. P. Guiard (2016). \u00ab\u00a0Genetic dysfunction of serotonin 2A receptor hampers response to antidepressant drugs: A translational approach.\u00a0\u00bb Neuropharmacology 105<\/strong>: 142-153.<\/a><\/p>\n\n\n\n

<\/p>\n\n\n\n

Nautiyal, K. M., L. Tritschler, S. E. Ahmari, D. J. David, A. M. Gardier and R. Hen (2016). \u00ab\u00a0A Lack of Serotonin 1B Autoreceptors Results in Decreased Anxiety and Depression-Related Behaviors.\u00a0\u00bb Neuropsychopharmacology 41<\/strong>(12): 2941-2950.<\/a><\/p>\n\n\n\n

<\/p>\n\n\n\n

David, D. J., L. Tritschler, J. P. Guilloux, A. M. Gardier, C. Sanchez and R. Gaillard (2016). \u00ab\u00a0[Pharmacological properties of vortioxetine and its pre-clinical consequences].\u00a0\u00bb Encephale 42<\/strong>(1 Suppl 1): 1S12-23.<\/a><\/p>\n\n\n\n

<\/p>\n\n\n\n

David, D. J. and D. Gourion (2016). \u00ab\u00a0[Antidepressant and tolerance: Determinants and management of major side effects].\u00a0\u00bb Encephale 42<\/strong>(6): 553-561.<\/a><\/p>\n\n\n\n

<\/p>\n\n\n\n

David, D. J. and A. M. Gardier (2016). \u00ab\u00a0[The pharmacological basis of the serotonin system: Application to antidepressant response].\u00a0\u00bb Encephale 42<\/strong>(3): 255-263.<\/a><\/p>\n\n\n\n

<\/p>\n\n\n\n

Darcet, F., A. M. Gardier, R. Gaillard, D. J. David and J. P. Guilloux (2016). \u00ab\u00a0Cognitive Dysfunction in Major Depressive Disorder. A Translational Review in Animal Models of the Disease.\u00a0\u00bb Pharmaceuticals (Basel) 9<\/strong>(1).<\/a><\/p>\n\n\n\n

<\/p>\n\n\n\n

Darcet, F., A. M. Gardier, D. J. David and J. P. Guilloux (2016). \u00ab\u00a0Chronic 5-HT4 receptor agonist treatment restores learning and memory deficits in a neuroendocrine mouse model of anxiety\/depression.\u00a0\u00bb Neurosci Lett 616<\/strong>: 197-203.<\/a><\/p>\n\n\n\n

<\/p>\n\n\n\n

Costemale-Lacoste, J. F., J. P. Guilloux and R. Gaillard (2016). \u00ab\u00a0The role of GSK-3 in treatment-resistant depression and links with the pharmacological effects of lithium and ketamine: A review of the literature.\u00a0\u00bb Encephale 42<\/strong>(2): 156-164.<\/a><\/p>\n\n\n\n

<\/p>\n\n\n\n

Corvol, J. C., S. Goni, R. Bordet and R. T. N. participants of the Giens Xxxi (2016). \u00ab\u00a0Translational research on cognitive and behavioural disorders in neurological and psychiatric diseases.\u00a0\u00bb Therapie 71<\/strong>(1): 1-13, 15-26.<\/a><\/p>\n\n\n\n

<\/p>\n\n\n\n

Brachman, R. A., J. C. McGowan, J. N. Perusini, S. C. Lim, T. H. Pham, C. Faye, A. M. Gardier, I. Mendez-David, D. J. David, R. Hen and C. A. Denny (2016). \u00ab\u00a0Ketamine as a Prophylactic Against Stress-Induced Depressive-like Behavior.\u00a0\u00bb Biol Psychiatry 79<\/strong>(9): 776-786.<\/a><\/p>\n\n\n\n

<\/p>\n\n\n\n

Besson, M., S. Guiducci, S. Granon, J. P. Guilloux, B. Guiard, C. Reperant, P. Faure, S. Pons, G. Cannazza, M. Zoli, A. M. Gardier and U. Maskos (2016). \u00ab\u00a0Alterations in alpha5* nicotinic acetylcholine receptors result in midbrain- and hippocampus-dependent behavioural and neural impairments.\u00a0\u00bb Psychopharmacology (Berl) 233<\/strong>(18): 3297-3314.<\/a><\/p>\n\n\n\n

<\/p>\n\n\n\n

2015<\/h2>\n\n\n\n

<\/p>\n\n\n\n

Schloesser, R. J., S. Orvoen, D. V. Jimenez, N. F. Hardy, K. R. Maynard, M. Sukumar, H. K. Manji, A. M. Gardier, D. J. David and K. Martinowich (2015). \u00ab\u00a0Antidepressant-like Effects of Electroconvulsive Seizures Require Adult Neurogenesis in a Neuroendocrine Model of Depression.\u00a0\u00bb Brain Stimul 8<\/strong>(5): 862-867.<\/a><\/p>\n\n\n\n

<\/p>\n\n\n\n

Nautiyal, K. M., K. F. Tanaka, M. M. Barr, L. Tritschler, Y. Le Dantec, D. J. David, A. M. Gardier, C. Blanco, R. Hen and S. E. Ahmari (2015). \u00ab\u00a0Distinct Circuits Underlie the Effects of 5-HT1B Receptors on Aggression and Impulsivity.\u00a0\u00bb Neuron 86<\/strong>(3): 813-826.<\/a><\/p>\n\n\n\n

<\/p>\n\n\n\n

Mendez-David, I., L. Tritschler, Z. E. Ali, M. H. Damiens, M. Pallardy, D. J. David, S. Kerdine-Romer and A. M. Gardier (2015). \u00ab\u00a0Nrf2-signaling and BDNF: A new target for the antidepressant-like activity of chronic fluoxetine treatment in a mouse model of anxiety\/depression.\u00a0\u00bb Neurosci Lett 597<\/strong>: 121-126.<\/a><\/p>\n\n\n\n

<\/p>\n\n\n\n

Mendez-David, I., D. J. David, J.-P. Guilloux, R. Hen and A. M. Gardier (2015). 5-HT4 Receptor Subtype, \u03b2-Arrestin Level, and Rapid-Onset Effects of Antidepressant Drugs. 95: <\/strong>101-121.<\/a><\/p>\n\n\n\n

<\/p>\n\n\n\n

Hache, G., B. P. Guiard, T. H. Nguyen, G. Quesseveur, A. M. Gardier, D. Peters, G. Munro and F. Coudore (2015). \u00ab\u00a0Antinociceptive activity of the new triple reuptake inhibitor NS18283 in a mouse model of chemotherapy-induced neuropathic pain.\u00a0\u00bb Eur J Pain 19<\/strong>(3): 322-333.<\/a><\/p>\n\n\n\n

<\/p>\n\n\n\n

\u00a0\u00bb target=\u00a0\u00bb_blank\u00a0\u00bb>Guilloux, J. P., S. Bassi, Y. Ding, C. Walsh, G. Turecki, G. Tseng, J. M. Cyranowski and E. Sibille (2015). \u00ab\u00a0Testing the predictive value of peripheral gene expression for nonremission following citalopram treatment for major depression.\u00a0\u00bb Neuropsychopharmacology 40<\/strong>(3): 701-710.<\/a><\/p>\n\n\n\n

<\/p>\n\n\n\n

Felice, D., O. F. O’Leary, J. F. Cryan, T. G. Dinan, A. M. Gardier, C. Sanchez and D. J. David (2015). \u00ab\u00a0When ageing meets the blues: Are current antidepressants effective in depressed aged patients?\u00a0\u00bb Neurosci Biobehav Rev 55<\/strong>: 478-497.<\/a><\/p>\n\n\n\n

<\/p>\n\n\n\n

Ding, Y., L. C. Chang, X. Wang, J. P. Guilloux, J. Parrish, H. Oh, B. J. French, D. A. Lewis, G. C. Tseng and E. Sibille (2015). \u00ab\u00a0Molecular and Genetic Characterization of Depression: Overlap with other Psychiatric Disorders and Aging.\u00a0\u00bb Mol Neuropsychiatry 1<\/strong>(1): 1-12.<\/a><\/p>\n\n\n\n

<\/p>\n\n\n\n

Courousse, T., A. Bacq, C. Belzung, B. Guiard, L. Balasse, F. Louis, A. M. Le Guisquet, A. M. Gardier, A. H. Schinkel, B. Giros and S. Gautron (2015). \u00ab\u00a0Brain organic cation transporter 2 controls response and vulnerability to stress and GSK3beta signaling.\u00a0\u00bb Mol Psychiatry 20<\/strong>(7): 889-900.<\/a><\/p>\n\n\n\n

<\/p>\n\n\n\n

Colle, R., F. Gressier, C. Verstuyft, E. Deflesselle, J. P. Lepine, F. Ferreri, P. Hardy, J. P. Guilloux, A. C. Petit, B. Feve, B. Falissard, L. Becquemont and E. Corruble (2015). \u00ab\u00a0Brain-derived neurotrophic factor Val66Met polymorphism and 6-month antidepressant remission in depressed Caucasian patients.\u00a0\u00bb J Affect Disord 175<\/strong>: 233-240.<\/a><\/p>\n\n\n\n

<\/p>\n\n\n\n

Colle, R., E. Deflesselle, S. Martin, D. J. David, P. Hardy, A. Taranu, B. Falissard, C. Verstuyft and E. Corruble (2015). \u00ab\u00a0BDNF\/TRKB\/P75NTR polymorphisms and their consequences on antidepressant efficacy in depressed patients.\u00a0\u00bb Pharmacogenomics 16<\/strong>(9): 997-1013.<\/a><\/p>\n\n\n\n

<\/p>\n\n\n\n

2014<\/h2>\n\n\n\n

<\/p>\n\n\n\n

Tritschler, L., D. Felice, R. Colle, J. P. Guilloux, E. Corruble, A. M. Gardier and D. J. David (2014). \u00ab\u00a0Vortioxetine for the treatment of major depressive disorder.\u00a0\u00bb Expert Rev Clin Pharmacol 7<\/strong>(6): 731-745.<\/a><\/p>\n\n\n\n

<\/p>\n\n\n\n

Samuels, B., I. David, D. J. David, A. M. Gardier and R. Hen (2014). Role of hippocampal neurogenesis in the mechanism of action of antidepressant\/anxiolytic drugs in animal model of depression and anxiety. Neurobiology of mood disorders. B. P. Guiard and E. Dremencov, Bentham Science Publishers: <\/strong>210-233.<\/p>\n\n\n\n

Quesseveur, G. and B. P. Guiard (2014). New Strategies for the Treatment of Mood Disorders: The Triple Reuptake Inhibitors. Neurobiology of mood disorders. B. P. Guiard and E. Dremencov, Bentham Science Publishers: <\/strong>234-253.<\/p>\n\n\n\n

<\/p>\n\n\n\n

Pla, P., S. Orvoen, F. Saudou, D. J. David and S. Humbert (2014). \u00ab\u00a0Mood disorders in Huntington’s disease: from behavior to cellular and molecular mechanisms.\u00a0\u00bb Front Behav Neurosci 8<\/strong>: 135.<\/a><\/p>\n\n\n\n

<\/p>\n\n\n\n

Petit, A. C., G. Quesseveur, F. Gressier, R. Colle, D. J. David, A. M. Gardier, F. Ferreri, J. P. Lepine, B. Falissard, C. Verstuyft, B. P. Guiard and E. Corruble (2014). \u00ab\u00a0Converging translational evidence for the involvement of the serotonin 2A receptor gene in major depressive disorder.\u00a0\u00bb Prog Neuropsychopharmacol Biol Psychiatry 54<\/strong>: 76-82.<\/a><\/p>\n\n\n\n

<\/p>\n\n\n\n

Mendez-David, I., D. J. David, F. Darcet, M. V. Wu, S. Kerdine-Romer, A. M. Gardier and R. Hen (2014). \u00ab\u00a0Rapid anxiolytic effects of a 5-HT(4) receptor agonist are mediated by a neurogenesis-independent mechanism.\u00a0\u00bb Neuropsychopharmacology 39<\/strong>(6): 1366-1378.<\/a><\/p>\n\n\n\n

<\/p>\n\n\n\n

Le Dantec, Y., G. Hache, J. P. Guilloux, B. P. Guiard, D. J. David, J. Adrien and P. Escourrou (2014). \u00ab\u00a0NREM sleep hypersomnia and reduced sleep\/wake continuity in a neuroendocrine mouse model of anxiety\/depression based on chronic corticosterone administration.\u00a0\u00bb Neuroscience 274<\/strong>: 357-368.<\/a><\/p>\n\n\n\n

<\/p>\n\n\n\n

Gaudin, A., M. Yemisci, H. Eroglu, S. Lepetre-Mouelhi, O. F. Turkoglu, B. Donmez-Demir, S. Caban, M. F. Sargon, S. Garcia-Argote, G. Pieters, O. Loreau, B. Rousseau, O. Tagit, N. Hildebrandt, Y. Le Dantec, J. Mougin, S. Valetti, H. Chacun, V. Nicolas, D. Desmaele, K. Andrieux, Y. Capan, T. Dalkara and P. Couvreur (2014). \u00ab\u00a0Squalenoyl adenosine nanoparticles provide neuroprotection after stroke and spinal cord injury.\u00a0\u00bb Nat Nanotechnol 9<\/strong>(12): 1054-1062.<\/a><\/p>\n\n\n\n

<\/p>\n\n\n\n

Gardier, A. M. (2014). Intracerebral in vivo microdialysis in knockout mice : advantages and drawbacks. Neurobiology of mood disorders. B. P. Guiard and E. Dremencov, Bentham Science Publishers: <\/strong>3-22.<\/p>\n\n\n\n

<\/p>\n\n\n\n

Darcet, F., I. Mendez-David, L. Tritschler, A. M. Gardier, J. P. Guilloux and D. J. David (2014). \u00ab\u00a0Learning and memory impairments in a neuroendocrine mouse model of anxiety\/depression.\u00a0\u00bb Front Behav Neurosci 8<\/strong>: 136.<\/a><\/p>\n\n\n\n

<\/p>\n\n\n\n

Ansar, S., E. Chatzikonstantinou, R. Thiagarajah, L. Tritschler, M. Fatar, M. G. Hennerici and S. Meairs (2014). \u00ab\u00a0Pro-inflammatory mediators and apoptosis correlate to rt-PA response in a novel mouse model of thromboembolic stroke.\u00a0\u00bb PLoS One 9<\/strong>(1): e85849.<\/a><\/p>\n\n\n\n

<\/p>\n\n\n\n

2013<\/h2>\n\n\n\n

<\/p>\n\n\n\n

Tolu, S., R. Eddine, F. Marti, V. David, M. Graupner, S. Pons, M. Baudonnat, M. Husson, M. Besson, C. Reperant, J. Zemdegs, C. Pages, Y. A. Hay, B. Lambolez, J. Caboche, B. Gutkin, A. M. Gardier, J. P. Changeux, P. Faure and U. Maskos (2013). \u00ab\u00a0Co-activation of VTA DA and GABA neurons mediates nicotine reinforcement.\u00a0\u00bb Mol Psychiatry 18<\/strong>(3): 382-393.<\/a><\/p>\n\n\n\n

<\/p>\n\n\n\n

Quesseveur, G., C. Reperant, D. J. David, A. M. Gardier, C. Sanchez and B. P. Guiard (2013). \u00ab\u00a05-HT(2)A receptor inactivation potentiates the acute antidepressant-like activity of escitalopram: involvement of the noradrenergic system.\u00a0\u00bb Exp Brain Res 226<\/strong>(2): 285-295.<\/a><\/p>\n\n\n\n

<\/p>\n\n\n\n

Quesseveur, G., A. M. Gardier and B. P. Guiard (2013). \u00ab\u00a0The monoaminergic tripartite synapse: a putative target for currently available antidepressant drugs.\u00a0\u00bb Curr Drug Targets 14<\/strong>(11): 1277-1294.<\/a><\/p>\n\n\n\n

<\/p>\n\n\n\n

Quesseveur, G., D. J. David, M. C. Gaillard, P. Pla, M. V. Wu, H. T. Nguyen, V. Nicolas, G. Auregan, I. David, A. Dranovsky, P. Hantraye, R. Hen, A. M. Gardier, N. Deglon and B. P. Guiard (2013). \u00ab\u00a0BDNF overexpression in mouse hippocampal astrocytes promotes local neurogenesis and elicits anxiolytic-like activities.\u00a0\u00bb Transl Psychiatry 3<\/strong>: e253.<\/a><\/p>\n\n\n\n

<\/p>\n\n\n\n

Pla, P., S. Orvoen, C. Benstaali, S. Dodier, A. M. Gardier, D. J. David, S. Humbert and F. Saudou (2013). \u00ab\u00a0Huntingtin acts non cell-autonomously on hippocampal neurogenesis and controls anxiety-related behaviors in adult mouse.\u00a0\u00bb PLoS One 8<\/strong>(9): e73902.<\/a><\/p>\n\n\n\n

<\/p>\n\n\n\n

Nguyen, H. T., B. P. Guiard, A. Bacq, D. J. David, I. David, G. Quesseveur, S. Gautron, C. Sanchez and A. M. Gardier (2013). \u00ab\u00a0Blockade of the high-affinity noradrenaline transporter (NET) by the selective 5-HT reuptake inhibitor escitalopram: an in vivo microdialysis study in mice.\u00a0\u00bb Br J Pharmacol 168<\/strong>(1): 103-116.<\/a><\/p>\n\n\n\n

<\/p>\n\n\n\n

Mendez-David, I., R. Hen, A. M. Gardier and D. J. David (2013). \u00ab\u00a0Adult hippocampal neurogenesis: an actor in the antidepressant-like action.\u00a0\u00bb Ann Pharm Fr 71<\/strong>(3): 143-149.<\/a><\/p>\n\n\n\n

<\/p>\n\n\n\n

Mendez-David, I., Z. El-Ali, R. Hen, B. Falissard, E. Corruble, A. M. Gardier, S. Kerdine-Romer and D. J. David (2013). \u00ab\u00a0A method for biomarker measurements in peripheral blood mononuclear cells isolated from anxious and depressed mice: beta-arrestin 1 protein levels in depression and treatment.\u00a0\u00bb Front Pharmacol 4<\/strong>: 124.<\/a><\/p>\n\n\n\n

<\/p>\n\n\n\n

Massicot, F., G. Hache, L. David, D. Chen, C. Leuxe, L. Garnier-Legrand, P. Rat, O. Laprevote and F. Coudore (2013). \u00ab\u00a0P2X7 Cell Death Receptor Activation and Mitochondrial Impairment in Oxaliplatin-Induced Apoptosis and Neuronal Injury: Cellular Mechanisms and In Vivo Approach.\u00a0\u00bb PLoS One 8<\/strong>(6): e66830.<\/a><\/p>\n\n\n\n

<\/p>\n\n\n\n

Guilloux, J. P., I. Mendez-David, A. Pehrson, B. P. Guiard, C. Reperant, S. Orvoen, A. M. Gardier, R. Hen, B. Ebert, S. Miller, C. Sanchez and D. J. David (2013). \u00ab\u00a0Antidepressant and anxiolytic potential of the multimodal antidepressant vortioxetine (Lu AA21004) assessed by behavioural and neurogenesis outcomes in mice.\u00a0\u00bb Neuropharmacology 73<\/strong>: 147-159.<\/a><\/p>\n\n\n\n

<\/p>\n\n\n\n

Guiard, B. (2013). \u00ab\u00a0Glia: a new cellular target in the treatment of major depression.\u00a0\u00bb Curr Drug Targets 14<\/strong>(11): 1219.<\/a><\/p>\n\n\n\n

<\/p>\n\n\n\n

 Gardier, A. M. (2013). \u00ab\u00a0Antidepressant activity: contribution of brain microdialysis in knock-out mice to the understanding of BDNF\/5-HT transporter\/5-HT autoreceptor interactions.\u00a0\u00bb Front Pharmacol 4<\/strong>: 98.<\/a><\/p>\n\n\n\n

<\/p>\n\n\n\n

Douillard-Guilloux, G., J. P. Guilloux, D. A. Lewis and E. Sibille (2013). \u00ab\u00a0Anticipated brain molecular aging in major depression.\u00a0\u00bb Am J Geriatr Psychiatry 21<\/strong>(5): 450-460.<\/a><\/p>\n\n\n\n

<\/p>\n\n\n\n

David, D. J., B. P. Guiard, J. P. Guilloux and A. M. Gardier (2013). Pharmacologie des antid\u00e9presseurs : mod\u00e8les animaux. Les Antid\u00e9presseurs. E. Corruble. Paris, Flammarion M\u00e9decine\/Sciences: <\/strong>40-51.<\/p>\n\n\n\n

<\/p>\n\n\n\n

Ben M’Barek, K., P. Pla, S. Orvoen, C. Benstaali, J. D. Godin, A. M. Gardier, F. Saudou, D. J. David and S. Humbert (2013). \u00ab\u00a0Huntingtin mediates anxiety\/depression-related behaviors and hippocampal neurogenesis.\u00a0\u00bb J Neurosci 33<\/strong>(20): 8608-8620.<\/a><\/p>\n\n\n\n

<\/p>\n\n\n\n

2012<\/h2>\n\n\n\n

<\/p>\n\n\n\n

Xia, L., C. Delomenie, I. David, Q. Rainer, M. Marouard, H. Delacroix, D. J. David, A. M. Gardier and J. P. Guilloux (2012). \u00ab\u00a0Ventral hippocampal molecular pathways and impaired neurogenesis associated with 5-HT(1)A and 5-HT(1)B receptors disruption in mice.\u00a0\u00bb Neurosci Lett 521<\/strong>(1): 20-25.<\/a><\/p>\n\n\n\n

<\/p>\n\n\n\n

Tripp, A., H. Oh, J. P. Guilloux, K. Martinowich, D. A. Lewis and E. Sibille (2012). \u00ab\u00a0Brain-derived neurotrophic factor signaling and subgenual anterior cingulate cortex dysfunction in major depressive disorder.\u00a0\u00bb Am J Psychiatry 169<\/strong>(11): 1194-1202.<\/a><\/p>\n\n\n\n

<\/p>\n\n\n\n

Rainer, Q., L. Xia, J. P. Guilloux, C. Gabriel, E. Mocaer, R. Hen, E. Enhamre, A. M. Gardier and D. J. David (2012). \u00ab\u00a0Beneficial behavioural and neurogenic effects of agomelatine in a model of depression\/anxiety.\u00a0\u00bb Int J Neuropsychopharmacol 15<\/strong>(3): 321-335.<\/a><\/p>\n\n\n\n

<\/p>\n\n\n\n

Rainer, Q., H. T. Nguyen, G. Quesseveur, A. M. Gardier, D. J. David and B. P. Guiard (2012). \u00ab\u00a0Functional status of somatodendritic serotonin 1A autoreceptor after long-term treatment with fluoxetine in a mouse model of anxiety\/depression based on repeated corticosterone administration.\u00a0\u00bb Mol Pharmacol 81<\/strong>(2): 106-112.<\/a><\/p>\n\n\n\n

<\/p>\n\n\n\n

Quesseveur, G., H. T. Nguyen, A. M. Gardier and B. P. Guiard (2012). \u00ab\u00a05-HT2 ligands in the treatment of anxiety and depression.\u00a0\u00bb Expert Opin Investig Drugs 21<\/strong>(11): 1701-1725.<\/a><\/p>\n\n\n\n

<\/p>\n\n\n\n

Orvoen, S., P. Pla, A. M. Gardier, F. Saudou and D. J. David (2012). \u00ab\u00a0Huntington’s disease knock-in male mice show specific anxiety-like behaviour and altered neuronal maturation.\u00a0\u00bb Neurosci Lett 507<\/strong>(2): 127-132.<\/a><\/p>\n\n\n\n

<\/p>\n\n\n\n

Hache, G., B. P. Guiard, Y. Le Dantec, S. Orvoen, D. J. David, A. M. Gardier and F. Coudore (2012). \u00ab\u00a0Antinociceptive effects of fluoxetine in a mouse model of anxiety\/depression.\u00a0\u00bb Neuroreport 23<\/strong>(9): 525-529.<\/a><\/p>\n\n\n\n

<\/p>\n\n\n\n

 Guilloux, J. P., G. Douillard-Guilloux, R. Kota, X. Wang, A. M. Gardier, K. Martinowich, G. C. Tseng, D. A. Lewis and E. Sibille (2012). \u00ab\u00a0Molecular evidence for BDNF- and GABA-related dysfunctions in the amygdala of female subjects with major depression.\u00a0\u00bb Mol Psychiatry 17<\/strong>(11): 1130-1142.<\/a><\/p>\n\n\n\n

<\/p>\n\n\n\n

Guilloux, J. P., D. J. David, B. A. Samuels, I. David, A. M. Gardier and B. P. Guiard (2012). Non-response to initial antidepressant therapy. Psychology. Rijeka, Croatia, InTech.<\/p>\n\n\n\n

<\/p>\n\n\n\n

Deltheil, T., B. Guiard, J. P. Guilloux, D. David, F. Coudore and A. M. Gardier (2012). S\u00e9rotonine et facteurs neurotrophiques dans la d\u00e9pression. S\u00e9rotonine: aspects biologiques et cliniques. O. Spreux-Varoquaux. Paris, Lavoisier – M\u00e9decine Sciences. 1: <\/strong>329-370.<\/p>\n\n\n\n

<\/p>\n\n\n\n

David, D. J. (2012). \u00ab\u00a0[Mechanisms of action of antidepressive drugs: new approaches].\u00a0\u00bb Encephale 38 Suppl 2<\/strong>: S45-48.<\/a><\/p>\n\n\n\n

<\/p>\n\n\n\n

Coudore, F., D. Roche, S. Lefeuvre, D. Faussot, E. M. Billaud, M. A. Loriot and P. Beaune (2012). \u00ab\u00a0Validation of an ultra-high performance liquid chromatography tandem mass spectrometric method for quantifying uracil and 5,6-dihydrouracil in human plasma.\u00a0\u00bb J Chromatogr Sci 50<\/strong>(10): 877-884.<\/a><\/p>\n\n\n\n

<\/p>\n\n\n\n

Besson, M., V. David, M. Baudonnat, P. Cazala, J. P. Guilloux, C. Reperant, I. Cloez-Tayarani, J. P. Changeux, A. M. Gardier and S. Granon (2012). \u00ab\u00a0Alpha7-nicotinic receptors modulate nicotine-induced reinforcement and extracellular dopamine outflow in the mesolimbic system in mice.\u00a0\u00bb Psychopharmacology (Berl) 220<\/strong>(1): 1-14.<\/a><\/p>\n\n\n\n

<\/p>\n\n\n\n

Bacq, A., L. Balasse, G. Biala, B. Guiard, A. M. Gardier, A. Schinkel, F. Louis, V. Vialou, M. P. Martres, C. Chevarin, M. Hamon, B. Giros and S. Gautron (2012). \u00ab\u00a0Organic cation transporter 2 controls brain norepinephrine and serotonin clearance and antidepressant response.\u00a0\u00bb Mol Psychiatry 17<\/strong>(9): 926-939.<\/a><\/p>\n\n\n\n

<\/p>\n\n\n\n

2011<\/h2>\n\n\n\n

<\/p>\n\n\n\n

Surget, A., A. Tanti, E. D. Leonardo, A. Laugeray, Q. Rainer, C. Touma, R. Palme, G. Griebel, Y. Ibarguen-Vargas, R. Hen and C. Belzung (2011). \u00ab\u00a0Antidepressants recruit new neurons to improve stress response regulation.\u00a0\u00bb Mol Psychiatry 16<\/strong>(12): 1177-1188.<\/a><\/p>\n\n\n\n

<\/p>\n\n\n\n

Samuels, B. A., E. D. Leonardo, R. Gadient, A. Williams, J. Zhou, D. J. David, A. M. Gardier, E. H. Wong and R. Hen (2011). \u00ab\u00a0Modeling treatment-resistant depression.\u00a0\u00bb Neuropharmacology 61<\/strong>(3): 408-413.<\/a><\/p>\n\n\n\n

Richardson-Jones, J. W., C. P. Craige, T. H. Nguyen, H. F. Kung, A. M. Gardier, A. Dranovsky, D. J. David, B. P. Guiard, S. G. Beck, R. Hen and E. D. Leonardo (2011). \u00ab\u00a0Serotonin-1A autoreceptors are necessary and sufficient for the normal formation of circuits underlying innate anxiety.\u00a0\u00bb J Neurosci 31<\/strong>(16): 6008-6018.<\/a><\/p>\n\n\n\n

<\/p>\n\n\n\n

Liotier, J. and F. Coudore (2011). \u00ab\u00a0Drug monitoring of a case of citalopram overdosage.\u00a0\u00bb Drug Chem Toxicol 34<\/strong>(4): 420-423.<\/a><\/p>\n\n\n\n

<\/p>\n\n\n\n

Hache, G., F. Coudore, A. M. Gardier and B. P. Guiard (2011). \u00ab\u00a0Monoaminergic Antidepressants in the Relief of Pain: Potential Therapeutic Utility of Triple Reuptake Inhibitors (TRIs).\u00a0\u00bb Pharmaceuticals 4<\/strong>(12): 285-342.<\/a><\/p>\n\n\n\n

<\/p>\n\n\n\n

Guilloux, J. P., M. Seney, N. Edgar and E. Sibille (2011). \u00ab\u00a0Integrated behavioral z-scoring increases the sensitivity and reliability of behavioral phenotyping in mice: relevance to emotionality and sex.\u00a0\u00bb J Neurosci Methods 197<\/strong>(1): 21-31.<\/a><\/p>\n\n\n\n

<\/p>\n\n\n\n

Guilloux, J. P., D. J. David, L. Xia, H. T. Nguyen, Q. Rainer, B. P. Guiard, C. Reperant, T. Deltheil, M. Toth, R. Hen and A. M. Gardier (2011). \u00ab\u00a0Characterization of 5-HT(1A\/1B)-\/- mice: an animal model sensitive to anxiolytic treatments.\u00a0\u00bb Neuropharmacology 61<\/strong>(3): 478-488.<\/a><\/p>\n\n\n\n

<\/p>\n\n\n\n

Guiard, B. (2011). A New Class of Antidepressant Drugs in the Treatment of Psychiatric Disorders: The Triple Reuptake Inhibitors. Psychiatric Disorders – Trends and development. T. Uehara. Rijeka, Croatia, InTech: <\/strong>291-316.<\/a><\/p>\n\n\n\n

<\/p>\n\n\n\n

2010<\/h2>\n\n\n\n

<\/p>\n\n\n\n

Richardson-Jones, J. W., C. P. Craige, B. P. Guiard, A. Stephen, K. L. Metzger, H. F. Kung, A. M. Gardier, A. Dranovsky, D. J. David, S. G. Beck, R. Hen and E. D. Leonardo (2010). \u00ab\u00a05-HT1A autoreceptor levels determine vulnerability to stress and response to antidepressants.\u00a0\u00bb Neuron 65<\/strong>(1): 40-52.<\/a><\/p>\n\n\n\n

<\/p>\n\n\n\n

Reperant, C., S. Pons, E. Dufour, H. Rollema, A. M. Gardier and U. Maskos (2010). \u00ab\u00a0Effect of the alpha4beta2* nicotinic acetylcholine receptor partial agonist varenicline on dopamine release in beta2 knock-out mice with selective re-expression of the beta2 subunit in the ventral tegmental area.\u00a0\u00bb Neuropharmacology 58<\/strong>(2): 346-350.<\/a><\/p>\n\n\n\n

<\/p>\n\n\n\n

Popa, D., J. Cerdan, C. Reperant, B. P. Guiard, J. P. Guilloux, D. J. David and A. M. Gardier (2010). \u00ab\u00a0A longitudinal study of 5-HT outflow during chronic fluoxetine treatment using a new technique of chronic microdialysis in a highly emotional mouse strain.\u00a0\u00bb Eur J Pharmacol 628<\/strong>(1-3): 83-90.<\/a><\/p>\n\n\n\n

<\/p>\n\n\n\n

Guilloux, J. P., C. Gaiteri and E. Sibille (2010). \u00ab\u00a0Network analysis of positional candidate genes of schizophrenia highlights…more than… myelin-related pathways.\u00a0\u00bb Mol Psychiatry 15<\/strong>(8): 786-788.<\/a><\/p>\n\n\n\n

<\/p>\n\n\n\n

Gaiteri, C., J. P. Guilloux, D. A. Lewis and E. Sibille (2010). \u00ab\u00a0Altered gene synchrony suggests a combined hormone-mediated dysregulated state in major depression.\u00a0\u00bb PLoS One 5<\/strong>(4): e9970.<\/a><\/p>\n\n\n\n

<\/p>\n\n\n\n

David, D. J., J. Wang, B. A. Samuels, Q. Rainer, I. David, A. M. Gardier and R. Hen (2010). \u00ab\u00a0Implications of the functional integration of adult-born hippocampal neurons in anxiety-depression disorders.\u00a0\u00bb Neuroscientist 16<\/strong>(5): 578-591.<\/a><\/p>\n\n\n\n

<\/p>\n\n\n\n

Cazorla, M., A. Jouvenceau, C. Rose, J. P. Guilloux, C. Pilon, A. Dranovsky and J. Premont (2010). \u00ab\u00a0Cyclotraxin-B, the first highly potent and selective TrkB inhibitor, has anxiolytic properties in mice.\u00a0\u00bb PLoS One 5<\/strong>(3): e9777.<\/a><\/p>\n\n\n\n

<\/p>\n\n\n\n

Amilhon, B., E. Lepicard, T. Renoir, R. Mongeau, D. Popa, O. Poirel, S. Miot, C. Gras, A. M. Gardier, J. Gallego, M. Hamon, L. Lanfumey, B. Gasnier, B. Giros and S. El Mestikawy (2010). \u00ab\u00a0VGLUT3 (vesicular glutamate transporter type 3) contribution to the regulation of serotonergic transmission and anxiety.\u00a0\u00bb J Neurosci 30<\/strong>(6): 2198-2210.<\/a><\/p>\n\n\n\n

<\/p>\n\n\n\n

2009<\/h2>\n\n\n\n

<\/p>\n\n\n\n

Real, C., I. Seif, J. Adrien and P. Escourrou (2009). \u00ab\u00a0Ondansetron and fluoxetine reduce sleep apnea in mice lacking monoamine oxidase A.\u00a0\u00bb Respir Physiol Neurobiol 168<\/strong>(3): 230-238.<\/a><\/p>\n\n\n\n

<\/p>\n\n\n\n

Rainer, Q., A. M. Gardier, R. Hen and D. J. David (2009). \u00ab\u00a0[Neurogenesis-dependent and independent effects of anti-depressant drugs].\u00a0\u00bb Med Sci (Paris) 25<\/strong>(10): 795-798.<\/a><\/p>\n\n\n\n

<\/p>\n\n\n\n

Ibarguen-Vargas, Y., A. Surget, P. Vourc’h, S. Leman, C. R. Andres, A. M. Gardier and C. Belzung (2009). \u00ab\u00a0Deficit in BDNF does not increase vulnerability to stress but dampens antidepressant-like effects in the unpredictable chronic mild stress.\u00a0\u00bb Behav Brain Res 202<\/strong>(2): 245-251.<\/a><\/p>\n\n\n\n

<\/p>\n\n\n\n

Guiard, B. P., M. El Mansari and P. Blier (2009). \u00ab\u00a0Prospect of a dopamine contribution in the next generation of antidepressant drugs: the triple reuptake inhibitors.\u00a0\u00bb Curr Drug Targets 10<\/strong>(11): 1069-1084.<\/a><\/p>\n\n\n\n

<\/p>\n\n\n\n

Gardier, A. M., B. P. Guiard, J. P. Guilloux, C. Reperant, F. Coudore and D. J. David (2009). \u00ab\u00a0Interest of using genetically manipulated mice as models of depression to evaluate antidepressant drugs activity: a review.\u00a0\u00bb Fundam Clin Pharmacol 23<\/strong>(1): 23-42.<\/a><\/p>\n\n\n\n

<\/p>\n\n\n\n

Gardier, A. M. (2009). \u00ab\u00a0Mutant mouse models and antidepressant drug research: focus on serotonin and brain-derived neurotrophic factor.\u00a0\u00bb Behav Pharmacol 20<\/strong>(1): 18-32.<\/a><\/p>\n\n\n\n

<\/p>\n\n\n\n

Deltheil, T., K. Tanaka, C. Reperant, R. Hen, D. J. David and A. M. Gardier (2009). \u00ab\u00a0Synergistic neurochemical and behavioural effects of acute intrahippocampal injection of brain-derived neurotrophic factor and antidepressants in adult mice.\u00a0\u00bb Int J Neuropsychopharmacol 12<\/strong>(7): 905-915.<\/a><\/p>\n\n\n\n

<\/p>\n\n\n\n

David, D. J., B. A. Samuels, Q. Rainer, J. W. Wang, D. Marsteller, I. Mendez, M. Drew, D. A. Craig, B. P. Guiard, J. P. Guilloux, R. P. Artymyshyn, A. M. Gardier, C. Gerald, I. A. Antonijevic, E. D. Leonardo and R. Hen (2009). \u00ab\u00a0Neurogenesis-dependent and -independent effects of fluoxetine in an animal model of anxiety\/depression.\u00a0\u00bb Neuron 62<\/strong>(4): 479-493.<\/a><\/p>\n\n\n\n

<\/p>\n\n\n\n

David, D. J., A. M. Gardier, J. Wang, B. Samuels and R. Hen (2009). Assay For Screening Antidepressant. Neuron. C. University and U. P. Sud. USA. 36682<\/strong>.<\/p>\n\n\n\n

<\/p>\n\n\n\n

Authier, N., D. Balayssac, F. Marchand, B. Ling, A. Zangarelli, J. Descoeur, F. Coudore, E. Bourinet and A. Eschalier (2009). \u00ab\u00a0Animal models of chemotherapy-evoked painful peripheral neuropathies.\u00a0\u00bb Neurotherapeutics 6<\/strong>(4): 620-629.<\/a><\/p>\n\n\n\n

<\/p>\n\n\n\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

2024 Nguyen, T. M. L., F. Jollant, L. Tritschler, R. Colle, E. Corruble and A. M. Gardier (2024). \u00ab\u00a0[Ketamine and suicidal behavior: Contribution of animal models of aggression-impulsivity to understanding its mechanism of action].\u00a0\u00bb Ann Pharm Fr 82(1): 3-14. Nguyen, T. M. L., J.-P. Guilloux, C. Defaix, I. Mendez-David, I. Etting, J.-C. Alvarez, J. C.…
Lire la suite<\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"_links":{"self":[{"href":"http:\/\/www.neuropharmacologie.universite-paris-saclay.fr\/index.php?rest_route=\/wp\/v2\/pages\/34"}],"collection":[{"href":"http:\/\/www.neuropharmacologie.universite-paris-saclay.fr\/index.php?rest_route=\/wp\/v2\/pages"}],"about":[{"href":"http:\/\/www.neuropharmacologie.universite-paris-saclay.fr\/index.php?rest_route=\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"http:\/\/www.neuropharmacologie.universite-paris-saclay.fr\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"http:\/\/www.neuropharmacologie.universite-paris-saclay.fr\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=34"}],"version-history":[{"count":32,"href":"http:\/\/www.neuropharmacologie.universite-paris-saclay.fr\/index.php?rest_route=\/wp\/v2\/pages\/34\/revisions"}],"predecessor-version":[{"id":613,"href":"http:\/\/www.neuropharmacologie.universite-paris-saclay.fr\/index.php?rest_route=\/wp\/v2\/pages\/34\/revisions\/613"}],"wp:attachment":[{"href":"http:\/\/www.neuropharmacologie.universite-paris-saclay.fr\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=34"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}